{"title":"Benactiv","description":"\u003cp\u003eBenactiv Gola a base di flurbiprofene, antinfiammatorio che agisce direttamente sulla mucosa infiammata. Disponibile in spray per mucosa orale, che raggiunge il punto dolente con poche erogazioni, e in pastiglie da sciogliere in bocca in più gusti. Spedizione veloce in 24\/48 ore.\u003c\/p\u003e","products":[{"product_id":"benactiv-gola-arancia-16-pastiglie","title":"Benactiv Throat Orange 16 Lozenges","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e Symptomatic treatment of irritative-inflammatory states also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e Symptomatic treatment of irritative-inflammatory conditions also associated with oropharyngeal pain (e.g. gingivitis, stomatitis, pharyngitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e 100 ml of mouthwash contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 250 mg Excipients with known effects: hydrogenated castor oil-40-polyoxyethylene, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene). \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e 100 ml of solution contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 250 mg Excipients with known effects: hydrogenated castor oil-40-polyoxyethylene, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene). \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e One tablet contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 8.75 mg Excipients with known effects: liquid glucose (containing sulphites and wheat starch), liquid sucrose, honey, lemon flavoring and levomenthol (containing butylated hydroxyanisole, citral, citronellol, d-limonene, farfalle, geraniol, linalool). \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e One tablet contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 8.75 mg Excipients with known effects: liquid maltitol (E965), isomalt (E953), orange flavoring and levomenthol (containing citral, citronellol, d-limonene, geraniol, linalool). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e Glycerol, ethanol (96 percent), sorbitol 70, hydrogenated castor oil-40-polyoxyethylene, sodium hydroxide, sodium saccharin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene), patent blue V (E131), purified water. \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e Glycerol, ethanol (96 percent), sorbitol 70, hydrogenated castor oil-40-polyoxyethylene, sodium hydroxide, sodium saccharin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene), patent blue V (E131), purified water. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e Liquid sucrose, liquid glucose (containing sulphites and wheat starch), macrogol 300, potassium hydroxide, lemon flavoring and levomenthol (containing butylated hydroxyanisole, citral, citronellol, d-limonene, farfalle, geraniol, linalool), honey. \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e Macrogol 300, potassium hydroxide, orange flavor and levomenthol (containing citral, citronellol, dlimonene, geraniol, linalool), acesulfame potassium (E950), liquid maltitol (E965), isomalt (E953).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not use the medicine in children under 12 years of age. Flurbiprofen is contraindicated in patients with known hypersensitivity to flurbiprofen or to any of the excipients listed in section 6.1. Patients who have previously shown hypersensitivity reactions (e.g. asthma, urticaria, allergy, rhinitis, angioedema, bronchospasm) towards ibuprofen, acetylsalicylic acid (aspirin) or other non-steroidal anti-inflammatory drugs (NSAIDs). Flurbiprofen is also contraindicated in patients with a history of gastrointestinal bleeding or perforation related to previous NSAID treatment. Flurbiprofen should not be taken by patients with active or anamnestic ulcerative colitis, Crohn's disease, recurrent peptic ulcer or gastrointestinal haemorrhage (defined as two or more distinct episodes of demonstrated ulceration or bleeding). Flurbiprofen is contraindicated in patients with severe heart failure, severe hepatic failure and renal failure (see section 4.4). Third trimester of pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.4). \u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: 2-3 rinses or gargles per day with 10 ml (1 scoop) of mouthwash. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3).\u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Rinse or keep in mouth while gargling for up to 1 minute. Do not ingest. The mouthwash can be used pure or diluted in half a glass of water. \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: apply one dose (2 sprays) 3 times a day, directed directly onto the affected part. Each spray delivers 0.2 ml of solution, equivalent to 0.5 mg of active ingredient. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3).\u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Direct the nozzle towards the back of the throat and spray on the affected part. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: 1 tablet every 3-6 hours, as needed. Do not exceed the dose of 8 tablets in 24 hours. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3).\u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Dissolve slowly in your mouth. As with all lozenges, in order to avoid local irritation, flurbiprofen lozenges should also be moved inside the mouth during administration. If mouth irritation occurs, treatment should be discontinued.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenactiv Gola Orange flavored sugar-free lozenges and Benactiv Gola Lemon and Honey flavored lozenges: store at temperatures below 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt the recommended doses, when using the medicine in its various pharmaceutical forms, any swallowing does not cause any harm to the patient, as the dose of flurbiprofen is significantly lower than that commonly used in systemic treatments. Elderly: Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal haemorrhage and perforation, which may be fatal. \u003ci\u003eRespiratory disorders \u003c\/i\u003e Cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma or allergies. Flurbiprofen should be used with caution in these patients. \u003ci\u003eOther NSAIDs \u003c\/i\u003e It is advisable not to combine the medicine with other NSAIDs (see section 4.5). \u003ci\u003eSystemic lupus erythematosus (SLE) and mixed connective tissue disease \u003c\/i\u003e Patients with systemic lupus erythematosus and mixed connective tissue disease may have an increased risk of aseptic meningitis (see section 4.8), however this effect is not usually seen with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiac, hepatic and renal impairment \u003c\/i\u003e The medicine should be used with caution in patients with cardiac, renal or hepatic insufficiency. NSAIDs have been reported to cause various forms of nephrotoxicity, including interstitial nephritis, nephrotic syndrome, and renal failure. The administration of an NSAID can cause a dose-dependent reduction in the formation of prostaglandins and precipitate renal failure. Patients at highest risk of developing this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those on diuretic therapy and the elderly; however, this effect is not usually observed with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiovascular and cerebrovascular effects \u003c\/i\u003e Before starting treatment in patients with a positive history of hypertension and\/or heart failure, caution is required (discuss with your doctor or pharmacist), since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. Clinical studies and epidemiological data suggest that the use of some NSAIDs, especially at high doses and for long-term treatments, may be associated with a modest increase in the risk of arterial thrombotic events such as myocardial infarction or stroke. There are insufficient data to exclude a similar risk for flurbiprofen. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with flurbiprofen only after careful consideration. Similar considerations must be made before starting long-term treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking). \u003ci\u003eEffects on the central nervous system \u003c\/i\u003e Analgesic-induced headache. In case of prolonged or irregular use of analgesics, headache may occur, which must not be treated by increasing the dose of the medicine. \u003ci\u003eGastrointestinal effects\u003c\/i\u003e Flurbiprofen should be administered with caution to patients with a history of peptic ulcers and other gastrointestinal diseases as these conditions may be exacerbated. The risk of gastrointestinal haemorrhage, ulcer or perforation is higher with increasing dosage of flurbiprofen in patients with a history of ulcer, particularly if complicated by haemorrhage and perforation, and in the elderly. These patients should start treatment with the lowest available dose. Gastrointestinal bleeding, ulcer or perforation have been reported with all NSAIDs at any time during treatment. These adverse reactions can be fatal and can occur with or without warning symptoms or in case of a previous history of serious gastrointestinal reactions. Patients with a history of gastrointestinal disease, especially if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2). Caution should be advised in patients receiving concomitant medicinal products that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking flurbiprofen, treatment should be discontinued. \u003ci\u003eDermatological effects\u003c\/i\u003e The use of the medicine, especially if prolonged, can give rise to sensitization or local irritation phenomena. In such cases it is necessary to interrupt the treatment and consult a doctor to institute, if necessary, suitable therapy. Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Flurbiprofen should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003ci\u003eInfections\u003c\/i\u003e Since isolated cases of exacerbation of inflammation related to infections (e.g. development of necrotizing fasciitis) have been described in temporal association with the systemic use of drugs belonging to the NSAID class, patients are recommended to immediately consult a doctor in case of appearance or worsening of signs of a bacterial infection during flurbiprofen-based therapy. A possible indication for starting antibiotic therapy must be taken into consideration. If mouth irritation develops, treatment should be discontinued. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain para-hydroxybenzoates which can cause allergic reactions (even delayed). BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain hydrogenated 40-polyoxyethylene castor oil which may cause localized skin reactions. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain an aroma which in turn contains d-limonene. D-limonene can cause allergic reactions. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain less than 1 mmol (23mg) sodium per 10 ml dose, i.e. essentially \"sodium-free\". BENACTIV GOLA Lemon and Honey flavored lozenges contain liquid glucose, liquid sucrose and honey (invert sugar). Patients suffering from rare problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. To be taken into consideration in people with diabetes mellitus: this medicine contains 1.07 g of glucose and 1.41 g of sucrose per tablet. BENACTIV GOLA Lemon and Honey flavored lozenges contain sulphites. Rarely it can cause serious hypersensitivity reactions and bronchospasm. BENACTIV GOLA Lemon and Honey flavored lozenges contain only a very small amount of gluten (from wheat starch). This medicine is considered “gluten-free” and is very unlikely to cause problems for a celiac patient. One tablet contains no more than 21.38 micrograms of gluten. If a patient is allergic to wheat (condition other than celiac disease) he or she should not take this medicine. BENACTIV THROAT Lemon and Honey flavored lozenges contain an aroma which in turn contains citral, citronellol, d-limonene, farfalle, geraniol and linalool. Citral, citronellol, d-limonene, farfalle, geraniol and linalool can cause allergic reactions. BENACTIV THROAT Lemon and Honey flavored lozenges contain an aroma which in turn contains butylated hydroxyanisole which can cause localized skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucous membranes. BENACTIV GOLA Sugar-Free Lozenges Orange flavor is instead indicated for those patients who need to control their intake of sugars and calories. BENACTIV GOLA Orange flavored sugar-free lozenges contain an aroma which in turn contains citral, citronellol, d-limonene, geraniol and linalool. Citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. BENACTIV GOLA Orange flavored sugar-free lozenges contain liquid maltitol and isomalt. Patients with rare hereditary problems of fructose intolerance should not take this medicine. May have a mild laxative effect. The caloric value of maltitol and isomalt is 2.3 kcal\/g. Do not use for prolonged treatments beyond 7 days. If you do not notice appreciable results after 3 days of treatment, the cause could be a different pathological condition. In these cases it is advisable to consult your doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCaution should be exercised in patients treated with any of the medicines listed below, as interactions have been reported in some patients. However, inform your doctor if you are taking other medicines. Flurbiprofen should be avoided in association with: - Aspirin: unless the intake of low-dose aspirin (not exceeding 100 mg\/day or local prophylactic doses for cardiovascular protection) has been recommended by the doctor; As with other NSAID-containing medicinal products, concomitant administration of flurbiprofen and aspirin is generally not recommended due to the potential for increased side effects (see section 4.4). - Cox-2 inhibitors and other NSAIDs: concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to potential additive effects and an increased risk of adverse reactions (see section 4.4). Flurbiprofen should be used with caution in association with: - Anticoagulants: NSAIDs can potentiate the effects of anticoagulants such as warfarin (see section 4.4) - Antiaggregating agents: increased risk of gastrointestinal bleeding - Selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding - Antihypertensives (diuretics, ACE inhibitors and angiotensin II antagonists): i NSAIDs can reduce the effect of diuretics. Other antihypertensive drugs may potentiate nephrotoxicity caused by inhibition of cyclooxygenase, especially in patients with impaired renal function (these patients must be adequately hydrated) - Alcohol: may increase the risk of adverse reactions, especially bleeding in the gastrointestinal tract - Cardiac glycosides: NSAIDs may exacerbate heart failure, reduce GFR (glomerular filtration rate) and increase plasma levels of glycosides - Cyclosporine: increased risk of nephrotoxicity - Corticosteroids: increased risk of gastrointestinal ulcer or haemorrhage with NSAIDs (see section 4.4) - Lithium: there is evidence for a possible increase in plasma lithium levels - Methotrexate: there may be an increase in plasma levels of methotrexate - Mifepristone: NSAIDs should not be used for 8-12 days after administration of mifepristone, as NSAIDs may reduce the effect of mifepristone - Quinolone antibiotics: data obtained in animals indicate that NSAIDs may increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing seizures - Tacrolimus: possible increased risk of nephrotoxicity when NSAIDs are administered together with tacrolimus - Zidovudine: increased risk of haematological toxicity when NSAIDs are administered with zidovudine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity reactions to NSAIDs have been reported and these may consist of: (a) non-specific allergic reactions and anaphylaxis (b) respiratory tract reactivity, e.g. asthma, aggravated asthma, bronchospasm, dyspnoea (c) various skin disorders, including for example skin rashes of different types, pruritus, urticaria, purpura, angioedema and, more rarely, exfoliative and bullous dermatosis (including necrolysis epidermal and erythema multiforme). The most commonly observed adverse reactions are gastrointestinal in nature. Local use of the medicine, especially if prolonged, can give rise to local sensitization or irritation phenomena. The dissolution of the medicine in tablet form in the oral cavity may be accompanied by sensations of heat or tingling in the oropharynx. In such cases it is necessary to interrupt treatment and institute, if necessary, suitable therapy. The following side effects have been reported, particularly after the administration of formulations for systemic use. They refer to those detected with the use of flurbiprofen used short term and at doses compatible with the classification of self-medication medicines. When treating chronic conditions and for long periods of time, additional side effects may occur. The side effects associated with the use of flurbiprofen are divided below based on system organ classification and frequency. Frequency is defined as: very common (≥ 1\/10), common (≥1\/100, \u003c1\/10), uncommon (≥1\/1,000, \u003c1\/100), rare (≥1\/10,000, \u003c1\/1,000), very rare (\u003c1\/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003eDisorders of the blood and lymphatic system - Frequency: Not known. Adverse reactions: Anemia, thrombocytopenia, aplastic anemia and agranulocytosis.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Common. Adverse reactions: Dizziness, headache, paraesthesia.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Uncommon. Adverse reactions: Drowsiness.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Not known. Adverse reactions: Cerebrovascular accident, optic neuritis, migraine, confusional states, dizziness.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency: Rare. Adverse reactions: Anaphylactic reaction.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency: Not known. Adverse reactions: Angioedema, hypersensitivity\u003c\/p\u003e\n\u003cp\u003eEye disorders - Frequency: Not known. Adverse reactions: Vision impairment.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders - Frequency: Not known. Adverse reactions: Tinnitus.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders - Frequency: Not known. Adverse reactions: Heart failure, edema.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Frequency: Not known. Adverse reactions: Hypertension.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Common. Adverse reactions: Throat irritation.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Uncommon. Adverse reactions: Asthma, bronchospasm and dyspnea, oropharyngeal vesicular rash, oropharyngeal hypoesthesia.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Common. Adverse reactions: Diarrhoea, mouth ulceration, nausea, oral pain, oral paraesthesia, oropharyngeal pain, oral discomfort (hot or burning sensation, tingling in the mouth).\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Uncommon. Adverse reactions: Abdominal distension, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, glossodynia, dysgeusia, oral dysesthesia, vomiting.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Not known. Adverse reactions: Melena, haematemesis, gastrointestinal haemorrhage, colitis, exacerbation of Crohn's disease, gastritis, peptic ulcer, gastric perforation, ulcer haemorrhage.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Uncommon. Adverse reactions: Skin rash, itching.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Not known. Adverse reactions: Urticaria, purpura, bullous dermatitis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme).\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders - Frequency: Not known. Adverse reactions: Toxic nephropathy, tubulointerstitial nephritis and nephrotic syndrome, renal failure (as with other NSAIDs).\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and administration site conditions - Frequency: Uncommon. Adverse reactions: Pyrexia, pain.\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and conditions relating to the administration site - Frequency: Not known. Adverse reactions: Discomfort, tiredness.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders - Frequency: Not known. Adverse reactions: Hepatitis.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Frequency: Uncommon. Adverse reactions: Insomnia.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Frequency: Not known. Adverse reactions: Depression, hallucination.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGiven the reduced content of the active ingredient and its local use, it is unlikely that overdose situations may occur. \u003cb\u003eSymptoms\u003c\/b\u003e The majority of patients who ingest clinically large quantities of NSAIDs develop nausea, vomiting, gastrointestinal irritation, epigastric pain, or more rarely diarrhea. Tinnitus, headache and gastrointestinal bleeding are also possible. In more severe cases of NSAID intoxication, central nervous system toxicity is observed, manifested by drowsiness, occasionally excitability, blurred vision and disorientation or coma. Occasionally patients develop seizures. In case of severe NSAID intoxication, metabolic acidosis may occur and the prothrombin time\/INR may be prolonged, probably due to interference with the action of coagulation factors present in circulation. Acute renal failure and liver damage may occur. An exacerbation of asthma is possible in asthmatic subjects. \u003cb\u003eTreatment\u003c\/b\u003e Treatment should be symptomatic and supportive and should include maintaining a patent airway and monitoring cardiac function and vital signs until stabilization. Oral administration of activated charcoal and, if necessary, correction of serum electrolytes should be considered if the patient presents within one hour of ingesting a potentially toxic amount. Seizures should be treated with intravenous diazepam or lorazepam if they are frequent or prolonged. Administer bronchodilators for asthma. There is no specific antidote for flurbiprofen.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Flurbiprofen should not be administered during the first and second trimester of pregnancy unless strictly necessary. The use of flurbiprofen during the third trimester of pregnancy is contraindicated. \u003cu\u003eBreastfeeding\u003c\/u\u003e In a limited number of studies, flurbiprofen appears in breast milk in very low concentrations and is unlikely to have negative effects on the breastfed infant. However, administration of flurbiprofen is not recommended in breastfeeding mothers. \u003cu\u003eFertility\u003c\/u\u003e There is evidence to suggest that cyclooxygenase\/prostaglandin synthesis inhibitors may cause impairment of female fertility through an effect on ovulation. This is reversible upon discontinuation of treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt does not interfere with the ability to drive and use machinery.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":40207824552051,"sku":"033262078","price":12.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/reckitt-benckiser-h-it-spa-benactiv-gola-arancia-16-pastiglie-farmacia-dottor-tili-1213792732.webp?v=1767126886"},{"product_id":"benactiv-gola-miele-limone-16-pastiglie","title":"Benactiv Throat Honey Lemon 16 Lozenges","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e Symptomatic treatment of irritative-inflammatory states also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e Symptomatic treatment of irritative-inflammatory conditions also associated with oropharyngeal pain (e.g. gingivitis, stomatitis, pharyngitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e 100 ml of mouthwash contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 250 mg Excipients with known effects: hydrogenated castor oil-40-polyoxyethylene, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene). \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e 100 ml of solution contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 250 mg Excipients with known effects: hydrogenated castor oil-40-polyoxyethylene, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene). \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e One tablet contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 8.75 mg Excipients with known effects: liquid glucose (containing sulphites and wheat starch), liquid sucrose, honey, lemon flavoring and levomenthol (containing butylated hydroxyanisole, citral, citronellol, d-limonene, farfalle, geraniol, linalool). \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e One tablet contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 8.75 mg Excipients with known effects: liquid maltitol (E965), isomalt (E953), orange flavoring and levomenthol (containing citral, citronellol, d-limonene, geraniol, linalool). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e Glycerol, ethanol (96 percent), sorbitol 70, hydrogenated castor oil-40-polyoxyethylene, sodium hydroxide, sodium saccharin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene), patent blue V (E131), purified water. \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e Glycerol, ethanol (96 percent), sorbitol 70, hydrogenated castor oil-40-polyoxyethylene, sodium hydroxide, sodium saccharin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene), patent blue V (E131), purified water. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e Liquid sucrose, liquid glucose (containing sulphites and wheat starch), macrogol 300, potassium hydroxide, lemon flavoring and levomenthol (containing butylated hydroxyanisole, citral, citronellol, d-limonene, farfalle, geraniol, linalool), honey. \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e Macrogol 300, potassium hydroxide, orange flavor and levomenthol (containing citral, citronellol, dlimonene, geraniol, linalool), acesulfame potassium (E950), liquid maltitol (E965), isomalt (E953).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not use the medicine in children under 12 years of age. Flurbiprofen is contraindicated in patients with known hypersensitivity to flurbiprofen or to any of the excipients listed in section 6.1. Patients who have previously shown hypersensitivity reactions (e.g. asthma, urticaria, allergy, rhinitis, angioedema, bronchospasm) towards ibuprofen, acetylsalicylic acid (aspirin) or other non-steroidal anti-inflammatory drugs (NSAIDs). Flurbiprofen is also contraindicated in patients with a history of gastrointestinal bleeding or perforation related to previous NSAID treatment. Flurbiprofen should not be taken by patients with active or anamnestic ulcerative colitis, Crohn's disease, recurrent peptic ulcer or gastrointestinal haemorrhage (defined as two or more distinct episodes of demonstrated ulceration or bleeding). Flurbiprofen is contraindicated in patients with severe heart failure, severe hepatic failure and renal failure (see section 4.4). Third trimester of pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.4). \u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: 2-3 rinses or gargles per day with 10 ml (1 scoop) of mouthwash. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3).\u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Rinse or keep in mouth while gargling for up to 1 minute. Do not ingest. The mouthwash can be used pure or diluted in half a glass of water. \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: apply one dose (2 sprays) 3 times a day, directed directly onto the affected part. Each spray delivers 0.2 ml of solution, equivalent to 0.5 mg of active ingredient. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3).\u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Direct the nozzle towards the back of the throat and spray on the affected part. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: 1 tablet every 3-6 hours, as needed. Do not exceed the dose of 8 tablets in 24 hours. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3).\u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Dissolve slowly in your mouth. As with all lozenges, in order to avoid local irritation, flurbiprofen lozenges should also be moved inside the mouth during administration. If mouth irritation occurs, treatment should be discontinued.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenactiv Gola Orange flavored sugar-free lozenges and Benactiv Gola Lemon and Honey flavored lozenges: store at temperatures below 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt the recommended doses, when using the medicine in its various pharmaceutical forms, any swallowing does not cause any harm to the patient, as the dose of flurbiprofen is significantly lower than that commonly used in systemic treatments. Elderly: Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal haemorrhage and perforation, which may be fatal. \u003ci\u003eRespiratory disorders \u003c\/i\u003e Cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma or allergies. Flurbiprofen should be used with caution in these patients. \u003ci\u003eOther NSAIDs \u003c\/i\u003e It is advisable not to combine the medicine with other NSAIDs (see section 4.5). \u003ci\u003eSystemic lupus erythematosus (SLE) and mixed connective tissue disease \u003c\/i\u003e Patients with systemic lupus erythematosus and mixed connective tissue disease may have an increased risk of aseptic meningitis (see section 4.8), however this effect is not usually seen with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiac, hepatic and renal impairment \u003c\/i\u003e The medicine should be used with caution in patients with cardiac, renal or hepatic insufficiency. NSAIDs have been reported to cause various forms of nephrotoxicity, including interstitial nephritis, nephrotic syndrome, and renal failure. The administration of an NSAID can cause a dose-dependent reduction in the formation of prostaglandins and precipitate renal failure. Patients at highest risk of developing this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those on diuretic therapy and the elderly; however, this effect is not usually observed with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiovascular and cerebrovascular effects \u003c\/i\u003e Before starting treatment in patients with a positive history of hypertension and\/or heart failure, caution is required (discuss with your doctor or pharmacist), since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. Clinical studies and epidemiological data suggest that the use of some NSAIDs, especially at high doses and for long-term treatments, may be associated with a modest increase in the risk of arterial thrombotic events such as myocardial infarction or stroke. There are insufficient data to exclude a similar risk for flurbiprofen. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with flurbiprofen only after careful consideration. Similar considerations must be made before starting long-term treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking). \u003ci\u003eEffects on the central nervous system \u003c\/i\u003e Analgesic-induced headache. In case of prolonged or irregular use of analgesics, headache may occur, which must not be treated by increasing the dose of the medicine. \u003ci\u003eGastrointestinal effects\u003c\/i\u003e Flurbiprofen should be administered with caution to patients with a history of peptic ulcers and other gastrointestinal diseases as these conditions may be exacerbated. The risk of gastrointestinal haemorrhage, ulcer or perforation is higher with increasing dosage of flurbiprofen in patients with a history of ulcer, particularly if complicated by haemorrhage and perforation, and in the elderly. These patients should start treatment with the lowest available dose. Gastrointestinal bleeding, ulcer or perforation have been reported with all NSAIDs at any time during treatment. These adverse reactions can be fatal and can occur with or without warning symptoms or in case of a previous history of serious gastrointestinal reactions. Patients with a history of gastrointestinal disease, especially if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2). Caution should be advised in patients receiving concomitant medicinal products that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking flurbiprofen, treatment should be discontinued. \u003ci\u003eDermatological effects\u003c\/i\u003e The use of the medicine, especially if prolonged, can give rise to sensitization or local irritation phenomena. In such cases it is necessary to interrupt the treatment and consult a doctor to institute, if necessary, suitable therapy. Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Flurbiprofen should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003ci\u003eInfections\u003c\/i\u003e Since isolated cases of exacerbation of inflammation related to infections (e.g. development of necrotizing fasciitis) have been described in temporal association with the systemic use of drugs belonging to the NSAID class, patients are recommended to immediately consult a doctor in case of appearance or worsening of signs of a bacterial infection during flurbiprofen-based therapy. A possible indication for starting antibiotic therapy must be taken into consideration. If mouth irritation develops, treatment should be discontinued. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain para-hydroxybenzoates which can cause allergic reactions (even delayed). BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain hydrogenated 40-polyoxyethylene castor oil which may cause localized skin reactions. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain an aroma which in turn contains d-limonene. D-limonene can cause allergic reactions. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain less than 1 mmol (23mg) sodium per 10 ml dose, i.e. essentially \"sodium-free\". BENACTIV GOLA Lemon and Honey flavored lozenges contain liquid glucose, liquid sucrose and honey (invert sugar). Patients suffering from rare problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. To be taken into consideration in people with diabetes mellitus: this medicine contains 1.07 g of glucose and 1.41 g of sucrose per tablet. BENACTIV GOLA Lemon and Honey flavored lozenges contain sulphites. Rarely it can cause serious hypersensitivity reactions and bronchospasm. BENACTIV GOLA Lemon and Honey flavored lozenges contain only a very small amount of gluten (from wheat starch). This medicine is considered “gluten-free” and is very unlikely to cause problems for a celiac patient. One tablet contains no more than 21.38 micrograms of gluten. If a patient is allergic to wheat (condition other than celiac disease) he or she should not take this medicine. BENACTIV THROAT Lemon and Honey flavored lozenges contain an aroma which in turn contains citral, citronellol, d-limonene, farfalle, geraniol and linalool. Citral, citronellol, d-limonene, farfalle, geraniol and linalool can cause allergic reactions. BENACTIV THROAT Lemon and Honey flavored lozenges contain an aroma which in turn contains butylated hydroxyanisole which can cause localized skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucous membranes. BENACTIV GOLA Sugar-Free Lozenges Orange flavor is instead indicated for those patients who need to control their intake of sugars and calories. BENACTIV GOLA Orange flavored sugar-free lozenges contain an aroma which in turn contains citral, citronellol, d-limonene, geraniol and linalool. Citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. BENACTIV GOLA Orange flavored sugar-free lozenges contain liquid maltitol and isomalt. Patients with rare hereditary problems of fructose intolerance should not take this medicine. May have a mild laxative effect. The caloric value of maltitol and isomalt is 2.3 kcal\/g. Do not use for prolonged treatments beyond 7 days. If you do not notice appreciable results after 3 days of treatment, the cause could be a different pathological condition. In these cases it is advisable to consult your doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCaution should be exercised in patients treated with any of the medicines listed below, as interactions have been reported in some patients. However, inform your doctor if you are taking other medicines. Flurbiprofen should be avoided in association with: - Aspirin: unless the intake of low-dose aspirin (not exceeding 100 mg\/day or local prophylactic doses for cardiovascular protection) has been recommended by the doctor; As with other NSAID-containing medicinal products, concomitant administration of flurbiprofen and aspirin is generally not recommended due to the potential for increased side effects (see section 4.4). - Cox-2 inhibitors and other NSAIDs: concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to potential additive effects and an increased risk of adverse reactions (see section 4.4). Flurbiprofen should be used with caution in association with: - Anticoagulants: NSAIDs can potentiate the effects of anticoagulants such as warfarin (see section 4.4) - Antiaggregating agents: increased risk of gastrointestinal bleeding - Selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding - Antihypertensives (diuretics, ACE inhibitors and angiotensin II antagonists): i NSAIDs can reduce the effect of diuretics. Other antihypertensive drugs may potentiate nephrotoxicity caused by inhibition of cyclooxygenase, especially in patients with impaired renal function (these patients must be adequately hydrated) - Alcohol: may increase the risk of adverse reactions, especially bleeding in the gastrointestinal tract - Cardiac glycosides: NSAIDs may exacerbate heart failure, reduce GFR (glomerular filtration rate) and increase plasma levels of glycosides - Cyclosporine: increased risk of nephrotoxicity - Corticosteroids: increased risk of gastrointestinal ulcer or haemorrhage with NSAIDs (see section 4.4) - Lithium: there is evidence for a possible increase in plasma lithium levels - Methotrexate: there may be an increase in plasma levels of methotrexate - Mifepristone: NSAIDs should not be used for 8-12 days after administration of mifepristone, as NSAIDs may reduce the effect of mifepristone - Quinolone antibiotics: data obtained in animals indicate that NSAIDs may increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing seizures - Tacrolimus: possible increased risk of nephrotoxicity when NSAIDs are administered together with tacrolimus - Zidovudine: increased risk of haematological toxicity when NSAIDs are administered with zidovudine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity reactions to NSAIDs have been reported and these may consist of: (a) non-specific allergic reactions and anaphylaxis (b) respiratory tract reactivity, e.g. asthma, aggravated asthma, bronchospasm, dyspnoea (c) various skin disorders, including for example skin rashes of different types, pruritus, urticaria, purpura, angioedema and, more rarely, exfoliative and bullous dermatosis (including necrolysis epidermal and erythema multiforme). The most commonly observed adverse reactions are gastrointestinal in nature. Local use of the medicine, especially if prolonged, can give rise to local sensitization or irritation phenomena. The dissolution of the medicine in tablet form in the oral cavity may be accompanied by sensations of heat or tingling in the oropharynx. In such cases it is necessary to interrupt treatment and institute, if necessary, suitable therapy. The following side effects have been reported, particularly after the administration of formulations for systemic use. They refer to those detected with the use of flurbiprofen used short term and at doses compatible with the classification of self-medication medicines. When treating chronic conditions and for long periods of time, additional side effects may occur. The side effects associated with the use of flurbiprofen are divided below based on system organ classification and frequency. Frequency is defined as: very common (≥ 1\/10), common (≥1\/100, \u003c1\/10), uncommon (≥1\/1,000, \u003c1\/100), rare (≥1\/10,000, \u003c1\/1,000), very rare (\u003c1\/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003eDisorders of the blood and lymphatic system - Frequency: Not known. Adverse reactions: Anemia, thrombocytopenia, aplastic anemia and agranulocytosis.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Common. Adverse reactions: Dizziness, headache, paraesthesia.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Uncommon. Adverse reactions: Drowsiness.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Not known. Adverse reactions: Cerebrovascular accident, optic neuritis, migraine, confusional states, dizziness.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency: Rare. Adverse reactions: Anaphylactic reaction.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency: Not known. Adverse reactions: Angioedema, hypersensitivity\u003c\/p\u003e\n\u003cp\u003eEye disorders - Frequency: Not known. Adverse reactions: Vision impairment.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders - Frequency: Not known. Adverse reactions: Tinnitus.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders - Frequency: Not known. Adverse reactions: Heart failure, edema.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Frequency: Not known. Adverse reactions: Hypertension.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Common. Adverse reactions: Throat irritation.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Uncommon. Adverse reactions: Asthma, bronchospasm and dyspnea, oropharyngeal vesicular rash, oropharyngeal hypoesthesia.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Common. Adverse reactions: Diarrhoea, mouth ulceration, nausea, oral pain, oral paraesthesia, oropharyngeal pain, oral discomfort (hot or burning sensation, tingling in the mouth).\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Uncommon. Adverse reactions: Abdominal distension, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, glossodynia, dysgeusia, oral dysesthesia, vomiting.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Not known. Adverse reactions: Melena, haematemesis, gastrointestinal haemorrhage, colitis, exacerbation of Crohn's disease, gastritis, peptic ulcer, gastric perforation, ulcer haemorrhage.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Uncommon. Adverse reactions: Skin rash, itching.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Not known. Adverse reactions: Urticaria, purpura, bullous dermatitis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme).\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders - Frequency: Not known. Adverse reactions: Toxic nephropathy, tubulointerstitial nephritis and nephrotic syndrome, renal failure (as with other NSAIDs).\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and administration site conditions - Frequency: Uncommon. Adverse reactions: Pyrexia, pain.\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and conditions relating to the administration site - Frequency: Not known. Adverse reactions: Discomfort, tiredness.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders - Frequency: Not known. Adverse reactions: Hepatitis.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Frequency: Uncommon. Adverse reactions: Insomnia.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Frequency: Not known. Adverse reactions: Depression, hallucination.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGiven the reduced content of the active ingredient and its local use, it is unlikely that overdose situations may occur. \u003cb\u003eSymptoms\u003c\/b\u003e The majority of patients who ingest clinically large quantities of NSAIDs develop nausea, vomiting, gastrointestinal irritation, epigastric pain, or more rarely diarrhea. Tinnitus, headache and gastrointestinal bleeding are also possible. In more severe cases of NSAID intoxication, central nervous system toxicity is observed, manifested by drowsiness, occasionally excitability, blurred vision and disorientation or coma. Occasionally patients develop seizures. In case of severe NSAID intoxication, metabolic acidosis may occur and the prothrombin time\/INR may be prolonged, probably due to interference with the action of coagulation factors present in circulation. Acute renal failure and liver damage may occur. An exacerbation of asthma is possible in asthmatic subjects. \u003cb\u003eTreatment\u003c\/b\u003e Treatment should be symptomatic and supportive and should include maintaining a patent airway and monitoring cardiac function and vital signs until stabilization. Oral administration of activated charcoal and, if necessary, correction of serum electrolytes should be considered if the patient presents within one hour of ingesting a potentially toxic amount. Seizures should be treated with intravenous diazepam or lorazepam if they are frequent or prolonged. Administer bronchodilators for asthma. There is no specific antidote for flurbiprofen.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Flurbiprofen should not be administered during the first and second trimester of pregnancy unless strictly necessary. The use of flurbiprofen during the third trimester of pregnancy is contraindicated. \u003cu\u003eBreastfeeding\u003c\/u\u003e In a limited number of studies, flurbiprofen appears in breast milk in very low concentrations and is unlikely to have negative effects on the breastfed infant. However, administration of flurbiprofen is not recommended in breastfeeding mothers. \u003cu\u003eFertility\u003c\/u\u003e There is evidence to suggest that cyclooxygenase\/prostaglandin synthesis inhibitors may cause impairment of female fertility through an effect on ovulation. This is reversible upon discontinuation of treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt does not interfere with the ability to drive and use machinery.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":40720891445363,"sku":"033262027","price":12.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/products\/reckitt-benckiser-h-it-spa-benactiv-gola-miele-limone-16-pastiglie-farmacia-dottor-tili-1213792527.webp?v=1767131032"},{"product_id":"benactiv-gola-0-25-spray-per-mucosa-orale-15ml","title":"Benactiv Gola 0.25% spray for oral mucosa 15ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e Symptomatic treatment of irritative-inflammatory states also associated with pain in the oropharyngeal cavity (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e Symptomatic treatment of irritative-inflammatory conditions also associated with oropharyngeal pain (e.g. gingivitis, stomatitis, pharyngitis).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e 100 ml of mouthwash contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 250 mg Excipients with known effects: hydrogenated castor oil-40-polyoxyethylene, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene). \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e 100 ml of solution contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 250 mg Excipients with known effects: hydrogenated castor oil-40-polyoxyethylene, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene). \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e One tablet contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 8.75 mg Excipients with known effects: liquid glucose (containing sulphites and wheat starch), liquid sucrose, honey, lemon flavoring and levomenthol (containing butylated hydroxyanisole, citral, citronellol, d-limonene, farfalle, geraniol, linalool). \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e One tablet contains: \u003cb\u003eactive ingredient:\u003c\/b\u003e flurbiprofen 8.75 mg Excipients with known effects: liquid maltitol (E965), isomalt (E953), orange flavoring and levomenthol (containing citral, citronellol, d-limonene, geraniol, linalool). For the full list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e Glycerol, ethanol (96 percent), sorbitol 70, hydrogenated castor oil-40-polyoxyethylene, sodium hydroxide, sodium saccharin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene), patent blue V (E131), purified water. \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e Glycerol, ethanol (96 percent), sorbitol 70, hydrogenated castor oil-40-polyoxyethylene, sodium hydroxide, sodium saccharin, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence (containing d-limonene), patent blue V (E131), purified water. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e Liquid sucrose, liquid glucose (containing sulphites and wheat starch), macrogol 300, potassium hydroxide, lemon flavoring and levomenthol (containing butylated hydroxyanisole, citral, citronellol, d-limonene, farfalle, geraniol, linalool), honey. \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e Macrogol 300, potassium hydroxide, orange flavor and levomenthol (containing citral, citronellol, dlimonene, geraniol, linalool), acesulfame potassium (E950), liquid maltitol (E965), isomalt (E953).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not use the medicine in children under 12 years of age. Flurbiprofen is contraindicated in patients with known hypersensitivity to flurbiprofen or to any of the excipients listed in section 6.1. Patients who have previously shown hypersensitivity reactions (e.g. asthma, urticaria, allergy, rhinitis, angioedema, bronchospasm) towards ibuprofen, acetylsalicylic acid (aspirin) or other non-steroidal anti-inflammatory drugs (NSAIDs). Flurbiprofen is also contraindicated in patients with a history of gastrointestinal bleeding or perforation related to previous NSAID treatment. Flurbiprofen should not be taken by patients with active or anamnestic ulcerative colitis, Crohn's disease, recurrent peptic ulcer or gastrointestinal haemorrhage (defined as two or more distinct episodes of demonstrated ulceration or bleeding). Flurbiprofen is contraindicated in patients with severe heart failure, severe hepatic failure and renal failure (see section 4.4). Third trimester of pregnancy.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUndesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.4). \u003cb\u003eBENACTIV THROAT Mouthwash\u003c\/b\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: 2-3 rinses or gargles per day with 10 ml (1 scoop) of mouthwash. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3).\u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Rinse or keep in mouth while gargling for up to 1 minute. Do not ingest. The mouthwash can be used pure or diluted in half a glass of water. \u003cb\u003eBENACTIV THROAT Spray for oral mucosa\u003c\/b\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: apply one dose (2 sprays) 3 times a day, directed directly onto the affected part. Each spray delivers 0.2 ml of solution, equivalent to 0.5 mg of active ingredient. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3).\u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Direct the nozzle towards the back of the throat and spray on the affected part. \u003cb\u003eBENACTIV THROAT Lemon and Honey flavored lozenges\u003c\/b\u003e \u003cb\u003eBENACTIV GOLA Orange flavored sugar-free lozenges\u003c\/b\u003e \u003cu\u003eDosage\u003c\/u\u003e \u003ci\u003eAdults\u003c\/i\u003e: 1 tablet every 3-6 hours, as needed. Do not exceed the dose of 8 tablets in 24 hours. \u003ci\u003ePediatric population\u003c\/i\u003e Children over 12 years old: same as adults. Children under 12 years of age: Do not administer to children under 12 years of age (see section 4.3). \u003ci\u003eSpecial populations\u003c\/i\u003e \u003ci\u003eElderly\u003c\/i\u003e: The clinical data currently available are limited, therefore no recommendation regarding posology can be made. Elderly people are at greater risk of serious consequences in case of adverse reactions (see section 4.4). \u003ci\u003ePatients with liver failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate hepatic impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3). \u003ci\u003ePatients with renal failure\u003c\/i\u003e: A dosage reduction is not necessary in patients with mild to moderate renal impairment. Flurbiprofen is contraindicated in patients with severe hepatic impairment (see section 4.3).\u003cu\u003eMethod of administration\u003c\/u\u003e For oropharyngeal use. Dissolve slowly in your mouth. As with all lozenges, in order to avoid local irritation, flurbiprofen lozenges should also be moved inside the mouth during administration. If mouth irritation occurs, treatment should be discontinued.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenactiv Gola Orange flavored sugar-free lozenges and Benactiv Gola Lemon and Honey flavored lozenges: store at temperatures below 25°C.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAt the recommended doses, when using the medicine in its various pharmaceutical forms, any swallowing does not cause any harm to the patient, as the dose of flurbiprofen is significantly lower than that commonly used in systemic treatments. Elderly: Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal haemorrhage and perforation, which may be fatal. \u003ci\u003eRespiratory disorders \u003c\/i\u003e Cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma or allergies. Flurbiprofen should be used with caution in these patients. \u003ci\u003eOther NSAIDs \u003c\/i\u003e It is advisable not to combine the medicine with other NSAIDs (see section 4.5). \u003ci\u003eSystemic lupus erythematosus (SLE) and mixed connective tissue disease \u003c\/i\u003e Patients with systemic lupus erythematosus and mixed connective tissue disease may have an increased risk of aseptic meningitis (see section 4.8), however this effect is not usually seen with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiac, hepatic and renal impairment \u003c\/i\u003e The medicine should be used with caution in patients with cardiac, renal or hepatic insufficiency. NSAIDs have been reported to cause various forms of nephrotoxicity, including interstitial nephritis, nephrotic syndrome, and renal failure. The administration of an NSAID can cause a dose-dependent reduction in the formation of prostaglandins and precipitate renal failure. Patients at highest risk of developing this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those on diuretic therapy and the elderly; however, this effect is not usually observed with products intended for limited and short-term use such as flurbiprofen. \u003ci\u003eCardiovascular and cerebrovascular effects \u003c\/i\u003e Before starting treatment in patients with a positive history of hypertension and\/or heart failure, caution is required (discuss with your doctor or pharmacist), since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. Clinical studies and epidemiological data suggest that the use of some NSAIDs, especially at high doses and for long-term treatments, may be associated with a modest increase in the risk of arterial thrombotic events such as myocardial infarction or stroke. There are insufficient data to exclude a similar risk for flurbiprofen. Patients with uncontrolled hypertension, congestive heart failure, established ischemic heart disease, peripheral arterial disease and\/or cerebrovascular disease should be treated with flurbiprofen only after careful consideration. Similar considerations must be made before starting long-term treatment in patients with risk factors for cardiovascular disease (e.g. hypertension, hyperlipidemia, diabetes mellitus, smoking). \u003ci\u003eEffects on the central nervous system \u003c\/i\u003e Analgesic-induced headache. In case of prolonged or irregular use of analgesics, headache may occur, which must not be treated by increasing the dose of the medicine. \u003ci\u003eGastrointestinal effects\u003c\/i\u003e Flurbiprofen should be administered with caution to patients with a history of peptic ulcers and other gastrointestinal diseases as these conditions may be exacerbated. The risk of gastrointestinal haemorrhage, ulcer or perforation is higher with increasing dosage of flurbiprofen in patients with a history of ulcer, particularly if complicated by haemorrhage and perforation, and in the elderly. These patients should start treatment with the lowest available dose. Gastrointestinal bleeding, ulcer or perforation have been reported with all NSAIDs at any time during treatment. These adverse reactions can be fatal and can occur with or without warning symptoms or in case of a previous history of serious gastrointestinal reactions. Patients with a history of gastrointestinal disease, especially if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms (see section 4.2). Caution should be advised in patients receiving concomitant medicinal products that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking flurbiprofen, treatment should be discontinued. \u003ci\u003eDermatological effects\u003c\/i\u003e The use of the medicine, especially if prolonged, can give rise to sensitization or local irritation phenomena. In such cases it is necessary to interrupt the treatment and consult a doctor to institute, if necessary, suitable therapy. Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see section 4.8). Flurbiprofen should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. \u003ci\u003eInfections\u003c\/i\u003e Since isolated cases of exacerbation of inflammation related to infections (e.g. development of necrotizing fasciitis) have been described in temporal association with the systemic use of drugs belonging to the NSAID class, patients are recommended to immediately consult a doctor in case of appearance or worsening of signs of a bacterial infection during flurbiprofen-based therapy. A possible indication for starting antibiotic therapy must be taken into consideration. If mouth irritation develops, treatment should be discontinued. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain para-hydroxybenzoates which can cause allergic reactions (even delayed). BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain hydrogenated 40-polyoxyethylene castor oil which may cause localized skin reactions. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain an aroma which in turn contains d-limonene. D-limonene can cause allergic reactions. BENACTIV GOLA Mouthwash and BENACTIV GOLA Spray contain less than 1 mmol (23mg) sodium per 10 ml dose, i.e. essentially \"sodium-free\". BENACTIV GOLA Lemon and Honey flavored lozenges contain liquid glucose, liquid sucrose and honey (invert sugar). Patients suffering from rare problems of fructose intolerance, glucose-galactose malabsorption or sucrase isomaltase insufficiency should not take this medicine. To be taken into consideration in people with diabetes mellitus: this medicine contains 1.07 g of glucose and 1.41 g of sucrose per tablet. BENACTIV GOLA Lemon and Honey flavored lozenges contain sulphites. Rarely it can cause serious hypersensitivity reactions and bronchospasm. BENACTIV GOLA Lemon and Honey flavored lozenges contain only a very small amount of gluten (from wheat starch). This medicine is considered “gluten-free” and is very unlikely to cause problems for a celiac patient. One tablet contains no more than 21.38 micrograms of gluten. If a patient is allergic to wheat (condition other than celiac disease) he or she should not take this medicine. BENACTIV THROAT Lemon and Honey flavored lozenges contain an aroma which in turn contains citral, citronellol, d-limonene, farfalle, geraniol and linalool. Citral, citronellol, d-limonene, farfalle, geraniol and linalool can cause allergic reactions. BENACTIV THROAT Lemon and Honey flavored lozenges contain an aroma which in turn contains butylated hydroxyanisole which can cause localized skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucous membranes. BENACTIV GOLA Sugar-Free Lozenges Orange flavor is instead indicated for those patients who need to control their intake of sugars and calories. BENACTIV GOLA Orange flavored sugar-free lozenges contain an aroma which in turn contains citral, citronellol, d-limonene, geraniol and linalool. Citral, citronellol, d-limonene, geraniol and linalool can cause allergic reactions. BENACTIV GOLA Orange flavored sugar-free lozenges contain liquid maltitol and isomalt. Patients with rare hereditary problems of fructose intolerance should not take this medicine. May have a mild laxative effect. The caloric value of maltitol and isomalt is 2.3 kcal\/g. Do not use for prolonged treatments beyond 7 days. If you do not notice appreciable results after 3 days of treatment, the cause could be a different pathological condition. In these cases it is advisable to consult your doctor.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCaution should be exercised in patients treated with any of the medicines listed below, as interactions have been reported in some patients. However, inform your doctor if you are taking other medicines. Flurbiprofen should be avoided in association with: - Aspirin: unless the intake of low-dose aspirin (not exceeding 100 mg\/day or local prophylactic doses for cardiovascular protection) has been recommended by the doctor; As with other NSAID-containing medicinal products, concomitant administration of flurbiprofen and aspirin is generally not recommended due to the potential for increased side effects (see section 4.4). - Cox-2 inhibitors and other NSAIDs: concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided due to potential additive effects and an increased risk of adverse reactions (see section 4.4). Flurbiprofen should be used with caution in association with: - Anticoagulants: NSAIDs can potentiate the effects of anticoagulants such as warfarin (see section 4.4) - Antiaggregating agents: increased risk of gastrointestinal bleeding - Selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding - Antihypertensives (diuretics, ACE inhibitors and angiotensin II antagonists): i NSAIDs can reduce the effect of diuretics. Other antihypertensive drugs may potentiate nephrotoxicity caused by inhibition of cyclooxygenase, especially in patients with impaired renal function (these patients must be adequately hydrated) - Alcohol: may increase the risk of adverse reactions, especially bleeding in the gastrointestinal tract - Cardiac glycosides: NSAIDs may exacerbate heart failure, reduce GFR (glomerular filtration rate) and increase plasma levels of glycosides - Cyclosporine: increased risk of nephrotoxicity - Corticosteroids: increased risk of gastrointestinal ulcer or haemorrhage with NSAIDs (see section 4.4) - Lithium: there is evidence for a possible increase in plasma lithium levels - Methotrexate: there may be an increase in plasma levels of methotrexate - Mifepristone: NSAIDs should not be used for 8-12 days after administration of mifepristone, as NSAIDs may reduce the effect of mifepristone - Quinolone antibiotics: data obtained in animals indicate that NSAIDs may increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing seizures - Tacrolimus: possible increased risk of nephrotoxicity when NSAIDs are administered together with tacrolimus - Zidovudine: increased risk of haematological toxicity when NSAIDs are administered with zidovudine.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity reactions to NSAIDs have been reported and these may consist of: (a) non-specific allergic reactions and anaphylaxis (b) respiratory tract reactivity, e.g. asthma, aggravated asthma, bronchospasm, dyspnoea (c) various skin disorders, including for example skin rashes of different types, pruritus, urticaria, purpura, angioedema and, more rarely, exfoliative and bullous dermatosis (including necrolysis epidermal and erythema multiforme). The most commonly observed adverse reactions are gastrointestinal in nature. Local use of the medicine, especially if prolonged, can give rise to local sensitization or irritation phenomena. The dissolution of the medicine in tablet form in the oral cavity may be accompanied by sensations of heat or tingling in the oropharynx. In such cases it is necessary to interrupt treatment and institute, if necessary, suitable therapy. The following side effects have been reported, particularly after the administration of formulations for systemic use. They refer to those detected with the use of flurbiprofen used short term and at doses compatible with the classification of self-medication medicines. When treating chronic conditions and for long periods of time, additional side effects may occur. The side effects associated with the use of flurbiprofen are divided below based on system organ classification and frequency. Frequency is defined as: very common (≥ 1\/10), common (≥1\/100, \u003c1\/10), uncommon (≥1\/1,000, \u003c1\/100), rare (≥1\/10,000, \u003c1\/1,000), very rare (\u003c1\/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.\u003c\/p\u003e\n\u003cp\u003eDisorders of the blood and lymphatic system - Frequency: Not known. Adverse reactions: Anemia, thrombocytopenia, aplastic anemia and agranulocytosis.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Common. Adverse reactions: Dizziness, headache, paraesthesia.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Uncommon. Adverse reactions: Drowsiness.\u003c\/p\u003e\n\u003cp\u003eNervous system disorders - Frequency: Not known. Adverse reactions: Cerebrovascular accident, optic neuritis, migraine, confusional states, dizziness.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency: Rare. Adverse reactions: Anaphylactic reaction.\u003c\/p\u003e\n\u003cp\u003eImmune system disorders - Frequency: Not known. Adverse reactions: Angioedema, hypersensitivity\u003c\/p\u003e\n\u003cp\u003eEye disorders - Frequency: Not known. Adverse reactions: Vision impairment.\u003c\/p\u003e\n\u003cp\u003eEar and labyrinth disorders - Frequency: Not known. Adverse reactions: Tinnitus.\u003c\/p\u003e\n\u003cp\u003eCardiac disorders - Frequency: Not known. Adverse reactions: Heart failure, edema.\u003c\/p\u003e\n\u003cp\u003eVascular disorders - Frequency: Not known. Adverse reactions: Hypertension.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Common. Adverse reactions: Throat irritation.\u003c\/p\u003e\n\u003cp\u003eRespiratory, thoracic and mediastinal disorders - Frequency: Uncommon. Adverse reactions: Asthma, bronchospasm and dyspnea, oropharyngeal vesicular rash, oropharyngeal hypoesthesia.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Common. Adverse reactions: Diarrhoea, mouth ulceration, nausea, oral pain, oral paraesthesia, oropharyngeal pain, oral discomfort (hot or burning sensation, tingling in the mouth).\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Uncommon. Adverse reactions: Abdominal distension, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, glossodynia, dysgeusia, oral dysesthesia, vomiting.\u003c\/p\u003e\n\u003cp\u003eGastrointestinal disorders - Frequency: Not known. Adverse reactions: Melena, haematemesis, gastrointestinal haemorrhage, colitis, exacerbation of Crohn's disease, gastritis, peptic ulcer, gastric perforation, ulcer haemorrhage.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Uncommon. Adverse reactions: Skin rash, itching.\u003c\/p\u003e\n\u003cp\u003eSkin and subcutaneous tissue disorders - Frequency: Not known. Adverse reactions: Urticaria, purpura, bullous dermatitis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme).\u003c\/p\u003e\n\u003cp\u003eRenal and urinary disorders - Frequency: Not known. Adverse reactions: Toxic nephropathy, tubulointerstitial nephritis and nephrotic syndrome, renal failure (as with other NSAIDs).\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and administration site conditions - Frequency: Uncommon. Adverse reactions: Pyrexia, pain.\u003c\/p\u003e\n\u003cp\u003eGeneral disorders and conditions relating to the administration site - Frequency: Not known. Adverse reactions: Discomfort, tiredness.\u003c\/p\u003e\n\u003cp\u003eHepatobiliary disorders - Frequency: Not known. Adverse reactions: Hepatitis.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Frequency: Uncommon. Adverse reactions: Insomnia.\u003c\/p\u003e\n\u003cp\u003ePsychiatric disorders - Frequency: Not known. Adverse reactions: Depression, hallucination.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGiven the reduced content of the active ingredient and its local use, it is unlikely that overdose situations may occur. \u003cb\u003eSymptoms\u003c\/b\u003e The majority of patients who ingest clinically large quantities of NSAIDs develop nausea, vomiting, gastrointestinal irritation, epigastric pain, or more rarely diarrhea. Tinnitus, headache and gastrointestinal bleeding are also possible. In more severe cases of NSAID intoxication, central nervous system toxicity is observed, manifested by drowsiness, occasionally excitability, blurred vision and disorientation or coma. Occasionally patients develop seizures. In case of severe NSAID intoxication, metabolic acidosis may occur and the prothrombin time\/INR may be prolonged, probably due to interference with the action of coagulation factors present in circulation. Acute renal failure and liver damage may occur. An exacerbation of asthma is possible in asthmatic subjects. \u003cb\u003eTreatment\u003c\/b\u003e Treatment should be symptomatic and supportive and should include maintaining a patent airway and monitoring cardiac function and vital signs until stabilization. Oral administration of activated charcoal and, if necessary, correction of serum electrolytes should be considered if the patient presents within one hour of ingesting a potentially toxic amount. Seizures should be treated with intravenous diazepam or lorazepam if they are frequent or prolonged. Administer bronchodilators for asthma. There is no specific antidote for flurbiprofen.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e Flurbiprofen should not be administered during the first and second trimester of pregnancy unless strictly necessary. The use of flurbiprofen during the third trimester of pregnancy is contraindicated. \u003cu\u003eBreastfeeding\u003c\/u\u003e In a limited number of studies, flurbiprofen appears in breast milk in very low concentrations and is unlikely to have negative effects on the breastfed infant. However, administration of flurbiprofen is not recommended in breastfeeding mothers. \u003cu\u003eFertility\u003c\/u\u003e There is evidence to suggest that cyclooxygenase\/prostaglandin synthesis inhibitors may cause impairment of female fertility through an effect on ovulation. This is reversible upon discontinuation of treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIt does not interfere with the ability to drive and use machinery.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":51131271971143,"sku":"033262041","price":11.07,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-h-it-spa-benactiv-gola-0-25-spray-per-mucosa-orale-15ml-farmacia-dottor-tili-1213792265.jpg?v=1767133307"},{"product_id":"benactivdol-gola-8-75mg-dose-spray-15ml","title":"Benactivdol Throat 8.75mg\/dose spray 15ml","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenactivdol Throat is indicated for the short-term symptomatic treatment of acute pain in sore throat in adults.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne spray contains 2.92 mg of Flurbiprofen, three \u003cb\u003edisbursements\u003c\/b\u003e equal to one dose contain 8.75 mg, corresponding to 16.2 mg\/ml of Flurbiprofen Excipients with known effects: Methyl parahydroxybenzoate (E218) 1.18 mg\/dose Propyl parahydroxybenzoate (E216) 0.24 mg\/dose Flavors containing allergens (mint flavor and cherry flavor) For the complete list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBetadex Dibasic sodium phosphate dodecahydrate Citric acid monohydrate Methyl parahydroxybenzoate (E218) Propyl parahydroxybenzoate (E216) Sodium hydroxide Mint flavor Cherry flavor N,2,3-Trimethyl-2-isopropylbutanamide Sodium saccharin (E954) Hydroxypropylbetadex Purified water Qualitative composition of the flavor Mint: Flavoring substances Flavoring preparation Propylene glycol E1520 Glyceryl triacetate (Triacetin) E1518 Qualitative composition of the flavor Cherry: Flavoring substances Flavoring preparation Propylene glycol E1520 Water\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. • Patients who have previously experienced hypersensitivity reactions (e.g. asthma, bronchospasm, rhinitis, angioedema or urticaria) in response to acetylsalicylic acid or other NSAIDs. • Patients with current or previous recurrent peptic ulcers\/haemorrhages (two or more distinct episodes of demonstrated ulceration) and intestinal ulceration. • Patients with a history of gastrointestinal bleeding or perforation, severe colitis, bleeding or haematopoietic disorders related to previous therapy with NSAIDs. • Last trimester of pregnancy (see section 4.6). • Severe heart failure, renal failure or hepatic failure (see section 4.4). • Children and adolescents under the age of 18.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDosage Only for short-term treatments. Indicated for adults over 18 years of age: One dose (3 sprays) directed to the affected part of the throat every 3-6 hours as needed, up to a maximum of 5 doses in a 24-hour period. \u003ci\u003ePediatric population\u003c\/i\u003e The safety and effectiveness of Benactivdol Gola in children or adolescents under 18 years of age have not been established. \u003ci\u003eElderly population\u003c\/i\u003e A general dosing recommendation cannot be given, as clinical experience to date is limited. Elderly people are at increased risk of serious consequences in case of adverse reactions. The lowest effective dose should be administered for the shortest possible duration of treatment to control symptoms (see section 4.4). Method of administration For oromucosal administration Do not inhale during delivery. This medicine should not be used for more than 3 days. Before use, it is necessary to activate the pump 4 times, pointing the nozzle away from your body, until a uniform and consistent mist is released. The pump is then ready for use. Between one use and another, dispense a minimum quantity of product, away from your body, in order to ensure that the nebulization is uniform and consistent. Before using the product, always make sure that the spray is uniform and consistent.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not refrigerate or freeze.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects can be minimized by using the lowest effective dose for the shortest duration of treatment needed to control symptoms. \u003cb\u003eInfections \u003c\/b\u003e Since isolated cases of exacerbation of inflammation related to infections (e.g. development of necrotizing fasciitis) have been described in temporal association with the systemic use of drugs belonging to the NSAID class, patients are recommended to immediately consult a doctor in case of appearance or worsening of signs of a bacterial infection during therapy based on flurbiprofen spray. A possible indication for starting antibiotic therapy must be taken into consideration. In case of purulent bacterial pharyngitis\/tonsillitis, the patient should consult the doctor for a re-evaluation of the treatment. Treatment should not be administered for more than 3 days. Treatment should be reevaluated if symptoms worsen or new symptoms occur. If mouth irritation develops, treatment with flurbirprofen should be discontinued. \u003cb\u003eElderly population \u003c\/b\u003e Elderly people experience an increased frequency of adverse reactions to NSAIDs, especially bleeding and gastrointestinal perforation, which can be fatal. \u003cb\u003eRespiratory disorders \u003c\/b\u003e Bronchospasm can be precipitated in patients suffering from or with a history of bronchial asthma or allergic disease, Flurbiprofen spray should be used with caution in these patients. \u003cb\u003eOther NSAIDs \u003c\/b\u003e The use of flurbiprofen spray should be avoided concomitantly with other NSAIDs, including selective cyclooxygenase-2 inhibitors (see section 4.5). \u003cb\u003eSystemic lupus erythematosus (SLE) and mixed connective tissue disease \u003c\/b\u003e Patients with systemic lupus erythematosus (SLE) and mixed connective tissue disease may be at increased risk of aseptic meningitis (see section 4.8), however this effect is not usually seen with products intended for short-term use such as flurbiprofen spray. \u003cb\u003eCardiovascular, renal and hepatic impairment \u003c\/b\u003e NSAIDs have been reported to cause various forms of nephrotoxicity, including interstitial nephritis, nephrotic syndrome, and renal failure. The administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and precipitate renal failure. Patients at highest risk of developing this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those on diuretic therapy and the elderly; this effect is not usually observed with products intended for short-term use such as flurbiprofen spray. \u003cb\u003eHepatic effects\u003c\/b\u003e Mild to moderate hepatic dysfunction (see sections 4.3 and 4.8). \u003cb\u003eCardiovascular and cerebrovascular effects \u003c\/b\u003e Before starting treatment in patients with a positive history of hypertension and\/or heart failure, caution is required (contact your doctor or pharmacist) since fluid retention, hypertension and edema have been reported in association with treatment with NSAIDs. Data from clinical and epidemiological studies suggest that the use of some NSAIDs (particularly at high doses and in long-term treatments) may be associated with a slight increase in the risk of arterial thrombotic events (for example myocardial infarction or stroke). There are insufficient data to exclude this risk with flurbiprofen when administered at a daily dosage of less than 5 times (3 actuations for each dose). \u003cb\u003eEffects on the central nervous system \u003c\/b\u003e Headache induced by analgesics - In case of prolonged or irregular use of analgesics, headache may occur, which must not be treated by increasing the dose of the medicine. \u003cb\u003eGastrointestinal disorders \u003c\/b\u003e NSAIDs should be administered with caution to patients with a history of gastrointestinal disorders (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). Gastrointestinal bleeding, ulceration or perforation, which may be fatal, have been reported with all NSAIDs at any time during treatment, in the presence or absence of warning symptoms or a history of serious gastrointestinal events. The risk of gastrointestinal bleeding, ulceration or perforation is higher with increasing doses of NSAIDs, in patients with a history of ulcer, especially if complicated with the presence of haemorrhage or perforation (see section 4.3) and in the elderly; this effect is not usually observed with products intended for short-term use such as flurbiprofen spray. Patients with a history of gastrointestinal toxicity, particularly the elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) to their healthcare provider. Caution should be advised in patients receiving concomitant medicinal products that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). When gastrointestinal bleeding or ulceration occurs in patients taking flurbiprofen, treatment should be discontinued. \u003cb\u003eHematological effects \u003c\/b\u003e Flurbiprofen, like other NSAIDs, can inhibit platelet aggregation and prolong bleeding time. Flurbiprofen spray should be used with caution in patients with potential bleeding abnormalities. \u003cb\u003eDermatological effects \u003c\/b\u003e Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported very rarely in association with the use of NSAIDs (see section 4.8). Flurbiprofen spray should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. This product contains methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reactions (sometimes even delayed). This medicine contains flavors containing citral, d-limonene, eugenol and linalool. Citral, d-limonene, eugenol and linalool can cause allergic reactions. This medicinal product contains less than 1 mmol sodium (23mg) per dose, i.e. essentially 'sodium-free'.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFlurbiprofen should be avoided in association with:\u003c\/p\u003e\n\u003cp\u003eOther NSAIDs including selective cyclooxygenase-2 inhibitors: Avoid concomitant use of two or more NSAIDs, as this may increase the risk of adverse effects (especially gastrointestinal adverse events such as ulcers and bleeding) (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eAcetylsalicylic acid (at low doses): Unless the intake of acetylsalicylic acid at low doses (not exceeding 75 mg\/day) has been recommended by the doctor (see section 4.4), since the potential risk of adverse events may increase.\u003c\/p\u003e\n\u003cp\u003eFlurbiprofen should be used with caution in association with:\u003c\/p\u003e\n\u003cp\u003eAnticoagulants: NSAIDs may potentiate the effects of anticoagulants such as warfarin (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eAntiplatelet agents: There is an increased risk of gastrointestinal ulceration or bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eAntihypertensive drugs (Diuretics, ACE inhibitors, Angiotensin II antagonists): NSAIDs can reduce the effect of diuretics. Other antihypertensive drugs may potentiate nephrotoxicity caused by cyclooxygenase inhibition, especially in patients with impaired renal function.\u003c\/p\u003e\n\u003cp\u003eAlcohol: May increase the risk of adverse reactions, especially bleeding in the gastrointestinal tract.\u003c\/p\u003e\n\u003cp\u003eCardiac glycosides: NSAIDs can exacerbate heart failure, reduce VGR (glomerular filtration rate) and increase plasma levels of glycosides - adequate monitoring and, if necessary, dose adjustment is recommended.\u003c\/p\u003e\n\u003cp\u003eCyclosporine: There is an increased risk of nephrotoxicity.\u003c\/p\u003e\n\u003cp\u003eCorticosteroids: There is an increased risk of gastrointestinal ulceration or bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eLithium: There may be an increase in serum lithium levels - adequate monitoring and, if necessary, dose adjustment is recommended.\u003c\/p\u003e\n\u003cp\u003eMethotrexate: The administration of NSAIDs within 24 hours before or after the administration of methotrexate can lead to high concentrations of methotrexate and an increase in its toxic effects.\u003c\/p\u003e\n\u003cp\u003eMifepristone: NSAIDs should not be used for 8 - 12 days following administration of mifepristone, as NSAIDs may reduce the effect of mifepristone.\u003c\/p\u003e\n\u003cp\u003eOral antidiabetics: Alterations in blood glucose levels have been reported (increasing the frequency of checks is recommended).\u003c\/p\u003e\n\u003cp\u003ePhenytoin: Serum levels of phenytoin may increase - adequate monitoring and, if necessary, dose adjustment is recommended.\u003c\/p\u003e\n\u003cp\u003ePotassium-sparing diuretics: Concomitant use may cause hyperkalemia.\u003c\/p\u003e\n\u003cp\u003eProbenecid and Sulfinpyrazone: Medicines containing probenecid and sulfinpyrazone may delay the excretion of flurbiprofen.\u003c\/p\u003e\n\u003cp\u003eQuinolone antibiotics: Animal data indicate that NSAIDs may increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may be at increased risk of developing seizures.\u003c\/p\u003e\n\u003cp\u003eSelective serotonin reuptake inhibitors (SSRIs): There is an increased risk of gastrointestinal ulceration or bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eTacrolimus: An increased risk of nephrotoxicity is possible when NSAIDs are administered concomitantly with tacrolimus.\u003c\/p\u003e\n\u003cp\u003eZidovudine: There is an increased risk of hematological toxicity when NSAIDs are administered with zidovudine.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePediatric population \u003c\/b\u003e No additional information is available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity reactions to NSAIDs have been reported and these may consist of: (a) non-specific allergic reactions and anaphylaxis (b) respiratory tract reactivity, e.g. asthma, asthma aggravated, bronchospasm, dyspnoea (c) various skin reactions, e.g. pruritus, urticaria, angioedema and, more rarely, exfoliative and bullous dermatosis (including epidermal necrolysis and erythema multiforme). Edema, hypertension and heart failure have been reported in association with treatment with NSAIDs. Data are insufficient to exclude this risk following the use of flurbiprofen oral mucosal spray, solution. \u003cb\u003eThe list of adverse effects reported below refers to the clinical evaluation carried out with flurbiprofen, used short term and at doses compatible with the OTC classification.\u003c\/b\u003e (Very common (≥1\/10), Common (≥1\/100 to \u003c1\/10), Uncommon (≥1\/1000 to \u003c1\/100), Rare (≥1\/10000 to \u003c1\/1000), Very rare (\u003c1\/10000), not known (frequency cannot be estimated from the available data)). \u003ci\u003ePathologies of the blood and lymphatic system\u003c\/i\u003e Not known: Anemia, Thrombocytopenia. \u003ci\u003eCardiac and vascular pathologies\u003c\/i\u003e Not known: Edema, Hypertension, Heart failure. \u003ci\u003eNervous system disorders\u003c\/i\u003e Common: Dizziness, Headache, Paraesthesia. Uncommon: Drowsiness. \u003ci\u003eRespiratory, thoracic and mediastinal disorders\u003c\/i\u003e Common: Throat irritation. Uncommon: exacerbation of asthma and bronchospasm, dyspnoea, wheezing, formation of blisters at the oropharyngeal level, pharyngeal hypoesthesia. \u003ci\u003eGastrointestinal disorders\u003c\/i\u003e Common: Diarrhoea, Mouth ulceration, Nausea, Oral pain, Oral paraesthesia, Oropharyngeal pain, Oral discomfort (hot or burning sensation, tingling in the mouth). Uncommon: Abdominal distension, Abdominal pain, Constipation, Dry mouth, Dyspepsia, Flatulence, Glossodynia, Dysgeusia, Oral dysesthesia, Vomiting. \u003ci\u003ePathologies of the skin and subcutaneous tissue\u003c\/i\u003e Uncommon: Skin rashes of various types, Itching. Not known: Severe skin reactions such as bullous reactions, including Stevens-Johnson Syndrome and Toxic Epidermal Necrosis. \u003ci\u003eSystemic pathologies and conditions relating to the administration site\u003c\/i\u003e Uncommon: Pyrexia, Pain. \u003ci\u003eImmune system disorders\u003c\/i\u003e Rare: Anaphylactic reaction. \u003ci\u003ePsychiatric disorders\u003c\/i\u003e Uncommon: Insomnia. \u003ci\u003eHepatobiliary disorders\u003c\/i\u003e Not known: Hepatitis \u003cb\u003eReporting of suspected adverse reactions \u003c\/b\u003e Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioniavverse\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSymptoms\u003c\/b\u003e The majority of patients who have ingested clinically large quantities of NSAIDs will develop nausea, vomiting, epigastric pain, or more rarely diarrhea. Tinnitus, headache and gastrointestinal bleeding are also possible. In more severe cases of NSAID intoxication, central nervous system toxicity is observed, manifested by drowsiness, occasionally excitability, blurred vision and disorientation or coma. Occasionally patients develop seizures. In case of severe NSAID intoxication, metabolic acidosis may occur and the prothrombin time\/INR may be prolonged, probably due to interference with the action of coagulation factors present in circulation. Acute renal failure and liver damage may occur. An exacerbation of asthma is possible in asthmatic subjects. \u003cb\u003eTreatment \u003c\/b\u003e Treatment should be symptomatic and supportive and should include maintaining a patent airway and monitoring cardiac function and vital signs until stabilization. Oral administration of activated charcoal or gastric lavage and, if necessary, correction of serum electrolytes should be considered if the patient presents within one hour of ingesting a potentially toxic amount. Seizures should be treated with intravenous diazepam or lorazepam if they are frequent or prolonged. Administer bronchodilators for asthma. There is no specific antidote for flurbiprofen.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003ePregnancy \u003c\/b\u003e Inhibition of prostaglandin synthesis can negatively influence pregnancy and\/or embryonic\/fetal development. Data obtained from epidemiological studies suggest an increased risk of miscarriage, cardiac malformations and gastroschisis following the use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiovascular malformations was increased from less than 1% to approximately 1.5%. The risk is thought to increase with the dose and duration of therapy. In animals, the administration of a prostaglandin synthesis inhibitor has been shown to cause an increase in pre- and post-implantation losses and embryo-foetal lethality. In addition, an increased incidence of several malformations, including cardiovascular ones, has been reported in animals administered a prostaglandin synthesis inhibitor during the organogenetic period. Flurbiprofen must not be administered during the first and second trimester of pregnancy. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose • the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction which may progress to renal failure with oligo-hydramnios. • the mother and newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, an anti-aggregating effect which can occur even at very low doses. - inhibition of uterine contractions resulting in a delay or prolongation of labor. Consequently, flurbiprofen is contraindicated during the third trimester of pregnancy (see section 4.3). \u003cb\u003eBreastfeeding \u003c\/b\u003e In a limited number of studies, flurbiprofen appears in breast milk at very low concentrations and is unlikely to have negative effects on the breastfed infant. However, due to the possible adverse effects of NSAIDs on breast-fed infants, the use of flurbiprofen spray by breastfeeding mothers is not recommended. \u003cb\u003eFertility \u003c\/b\u003e There is evidence to suggest that cyclooxygenase\/prostaglandin synthesis inhibitors may cause impairment of female fertility through an effect on ovulation. This is reversible upon discontinuation of treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo studies on the effects on the ability to drive and use machines have been performed. Dizziness, drowsiness and visual disturbances are side effects that can arise following the intake of NSAIDs. If these effects occur, patients should not drive or use machinery.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":51131346420039,"sku":"043050018","price":12.93,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-h-it-spa-benactivdol-gola-8-75mg-dose-spray-15ml-farmacia-dottor-tili-1213791987.jpg?v=1767149609"},{"product_id":"benactivdolmed-8-75-mg-dose-15-ml-spray-orale-limone-e-miele","title":"BenactivDolMed 8.75 mg\/dose 15 ml lemon and honey oral spray","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBenactivdolmed is indicated for the short-term symptomatic treatment of acute pain in sore throat in adults.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eACTIVE INGREDIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOne spray contains 2.92 mg of Flurbiprofen, a dose equal to three sprays contains 8.75 mg of Flurbiprofen, corresponding to 16.2 mg\/ml of Flurbiprofen. \u003cu\u003eExcipients with known effect:\u003c\/u\u003e Methyl parahydroxy benzoate (E218) 1.181 mg\/dose Propyl parahydroxy benzoate (E216) 0.2362 mg\/dose Flavorings contain allergens (lemon flavoring and honey flavouring) For the complete list of excipients, see section 6.1.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEXCIPIENTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBetadex, Disodium phosphate dodecahydrate, Citric acid monohydrate, Methyl parahydroxybenzoate (E218), Propyl parahydroxybenzoate (E216), Sodium hydroxide, Honey flavouring, Lemon flavouring, N,2,3-Trimethyl-2-isopropylbutanamide, Sodium saccharin (E954), Hydroxypropylbetadex, Purified water. Qualitative composition of Honey aroma: Flavoring substance(s), Flavoring preparation(s), Propylene glycol (E1520). Qualitative composition of the Lemon flavour: Flavoring substance(s), Flavoring preparation(s), Propylene glycol (E1520).\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONTRAINDICATIONS AND SIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e• Hypersensitivity to the active substance or to any of the excipients listed in paragraph 6.1. • Patients who have previously experienced hypersensitivity reactions (e.g. asthma, bronchospasm, rhinitis, angioedema or urticaria) in response to acetylsalicylic acid or other NSAIDs. • Current or previous peptic ulcer\/recurrent hemorrhage (two or more distinct episodes of demonstrated ulceration) and intestinal ulceration. • History of gastrointestinal bleeding or perforation, severe colitis, bleeding or haematopoietic disorders related to previous therapy with NSAIDs. • Last trimester of pregnancy (see section 4.6). • Severe heart failure, severe renal failure or severe hepatic failure (see section 4.4). • Children and adolescents under the age of 18.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOSAGE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003eDosage\u003c\/u\u003e: Only for short-term treatments. Adults aged 18 and over: one dose (3 sprays) administered to the back of the throat every 3-6 hours as needed, up to a maximum of 5 doses in a 24-hour period. \u003cb\u003ePediatric population\u003c\/b\u003e: The safety and effectiveness of Benactivdolmed in children or adolescents under 18 years of age have not been established. \u003cb\u003eElderly patients\u003c\/b\u003e: A general dosage recommendation cannot be given, as clinical experience to date is limited. Elderly people are at increased risk of serious consequences in case of adverse reactions. The lowest effective dose should be administered for the shortest duration of treatment needed to control symptoms (see section 4.4). \u003cu\u003eMethod of administration\u003c\/u\u003e: For oromucosal administration. Do not inhale while dispensing. This medicine should be used for a maximum of 3 days. Before first use, activate the pump, pointing the nozzle away from your body and spraying at least four times, until a fine, uniform mist is released. The pump is then activated and ready for use. Between uses, point the nozzle away from your body and dispense a minimum amount of product, in order to ensure that the atomization is fine and uniform. Before using the product, always make sure that the spray is fine and uniform.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONSERVATION\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDo not refrigerate or freeze.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWARNINGS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSide effects can be minimized by using the lowest effective dose for the shortest duration of treatment needed to control symptoms. \u003cu\u003eInfections\u003c\/u\u003e: Since an exacerbation of infectious inflammations (e.g. development of necrotizing fasciitis) has been described in isolated cases in temporal association with the systemic use of drugs belonging to the NSAID class, the patient is recommended to immediately consult a doctor in the event of the appearance or worsening of signs of a bacterial infection during therapy with flurbiprofen spray. Consideration should be given to whether initiation of antibiotic therapy is indicated. In case of purulent bacterial pharyngitis\/tonsillitis, the patient is advised to consult the doctor for a re-evaluation of the treatment. Treatment should be administered for a maximum of 3 days. If symptoms worsen or new symptoms appear, treatment should be reevaluated. If mouth irritation occurs, treatment with flurbirprofen should be discontinued. \u003cu\u003eElderly population\u003c\/u\u003e: Elderly people experience an increased frequency of adverse reactions to NSAIDs, especially bleeding and gastrointestinal perforation, which may be fatal. \u003cu\u003eRespiratory effects\u003c\/u\u003e: Bronchospasm may be precipitated in patients with or with a previous history of bronchial asthma or allergic disease. Flurbiprofen spray should be used with caution in these patients. \u003cu\u003eOther NSAIDs\u003c\/u\u003e: The use of flurbiprofen spray should be avoided concomitantly with other NSAIDs, including selective cyclooxygenase-2 inhibitors (see section 4.5). \u003cu\u003eSystemic lupus erythematosus (SLE) and mixed connective tissue disease\u003c\/u\u003e: Patients with systemic lupus erythematosus (SLE) and mixed connective tissue disease may have an increased risk of aseptic meningitis (see section 4.8), however this effect is not usually seen with products intended for limited and short-term use such as flurbiprofen spray. \u003cu\u003eCardiovascular, renal and hepatic impairment\u003c\/u\u003e: NSAIDs have been reported to cause various forms of nephrotoxicity, including interstitial nephritis, nephrotic syndrome, and renal failure. The administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and precipitate renal failure. Patients at greatest risk of developing this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, those on diuretic therapy and the elderly; however, this effect is not usually seen with products intended for limited, short-term use such as flurbiprofen spray. \u003cu\u003eHepatic effects\u003c\/u\u003e: Mild to moderate hepatic dysfunction (see sections 4.3 and 4.8). \u003cu\u003eCardiovascular and cerebrovascular effects\u003c\/u\u003e: Before starting treatment in patients with a history of hypertension and\/or heart failure, caution is required (contact your doctor or pharmacist) since fluid retention, hypertension and edema have been reported in association with NSAID therapy. Clinical studies and epidemiological data suggest that the use of some NSAIDs (particularly at high doses and in long-term treatment) may be associated with a slight increase in the risk of arterial thrombotic events (for example myocardial infarction or stroke). There are insufficient data to exclude this risk with flurbiprofen when administered at a daily dose not exceeding 5 doses (3 actuations for each dose). \u003cu\u003eEffects on the nervous system\u003c\/u\u003e: Headache induced by analgesics - In case of prolonged or irregular use of analgesics, headache may occur, which must not be treated by increasing the dose of the medicine. \u003cu\u003eGastrointestinal effects\u003c\/u\u003e: NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions may be exacerbated (see section 4.8). Gastrointestinal bleeding, ulceration or perforation, which may be fatal, have been reported with all NSAIDs at any time during treatment, with or without warning symptoms or a prior history of serious gastrointestinal events. The risk of gastrointestinal bleeding, ulceration or perforation is higher with increasing doses of NSAIDs, in patients with a history of ulcer, especially if complicated by haemorrhage or perforation (see section 4.3) and in the elderly; however, this effect is not usually observed with products intended for short-term limited use such as flurbiprofen spray. Patients with a history of gastrointestinal toxicity, particularly if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) to their doctor. Caution should be advised in patients receiving concomitant medicinal products that may increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or antiplatelet agents such as acetylsalicylic acid (see section 4.5). If gastrointestinal bleeding or ulceration occurs in patients taking flurbiprofen, treatment should be discontinued. \u003cu\u003eHematological effects\u003c\/u\u003e: Flurbiprofen, like other NSAIDs, can inhibit platelet aggregation and prolong bleeding time. Flurbiprofen spray should be used with caution in patients with potential for abnormal bleeding. \u003cu\u003eDermatological effects\u003c\/u\u003e: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported very rarely in association with the use of NSAIDs (see section 4.8). Flurbiprofen spray should be discontinued at the first appearance of skin rash, mucosal lesions or any other sign of hypersensitivity. This product contains methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reactions (sometimes delayed). This product contains less than 1 mmol (23 mg) sodium per dose, i.e. essentially “sodium-free”. Flavors containing allergens: This product contains flavors containing anisilic alcohol, citral, citronellol, d-Limonene, geraniol and linalool. Anisilic alcohol, citral, citronellol, d-Limonene, geraniol, linalool can cause allergic reactions.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eINTERACTIONS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFlurbiprofen should be avoided in association with:\u003c\/p\u003e\n\u003cp\u003eOther NSAIDs including selective cyclooxygenase-2 inhibitors: Avoid concomitant use of two or more NSAIDs, as this may increase the risk of adverse effects (especially gastrointestinal adverse events such as ulcers and bleeding) (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eAcetylsalicylic acid (low doses): Unless taking low doses of aspirin (not exceeding 75 mg\/day) has been recommended by your doctor, as the risk of adverse events may increase (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eFlurbiprofen should be used with caution in association with:\u003c\/p\u003e\n\u003cp\u003eAnticoagulants: NSAIDs may potentiate the effects of anticoagulants such as warfarin (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eAntiplatelet agents: There is an increased risk of gastrointestinal ulceration or bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eAntihypertensive drugs (Diuretics, ACE inhibitors, angiotensin II antagonists): NSAIDs can reduce the effect of diuretics and other antihypertensive drugs can potentiate the nephrotoxicity caused by the inhibition of cyclooxygenase, especially in patients with impaired renal function.\u003c\/p\u003e\n\u003cp\u003eAlcohol: May increase the risk of adverse reactions, especially bleeding in the gastrointestinal tract.\u003c\/p\u003e\n\u003cp\u003eCardiac glycosides: NSAIDs can exacerbate heart failure, reduce VGR (glomerular filtration rate) and increase plasma levels of glycosides - adequate monitoring and, if necessary, dose adjustment is recommended.\u003c\/p\u003e\n\u003cp\u003eCyclosporine: There is an increased risk of nephrotoxicity.\u003c\/p\u003e\n\u003cp\u003eCorticosteroids: There is an increased risk of gastrointestinal ulceration or bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eLithium: There may be an increase in serum lithium levels - adequate monitoring and, if necessary, dose adjustment is recommended.\u003c\/p\u003e\n\u003cp\u003eMethotrexate: The administration of NSAIDs within 24 hours before or after the administration of methotrexate can lead to high concentrations of methotrexate and an increase in its toxic effects.\u003c\/p\u003e\n\u003cp\u003eMifepristone: NSAIDs should not be used for 8 - 12 days after administration of mifepristone, as NSAIDs may reduce the effect of mifepristone.\u003c\/p\u003e\n\u003cp\u003eOral antidiabetics: Alterations in blood glucose levels have been reported (increasing the frequency of checks is recommended).\u003c\/p\u003e\n\u003cp\u003ePhenytoin: Serum levels of phenytoin may increase - adequate monitoring and, if necessary, dose adjustment is recommended.\u003c\/p\u003e\n\u003cp\u003ePotassium-sparing diuretics: Concomitant use may cause hyperkalemia.\u003c\/p\u003e\n\u003cp\u003eProbenecid and Sulfinpyrazone: Medicines containing probenecid and sulfinpyrazone may delay the excretion of flurbiprofen.\u003c\/p\u003e\n\u003cp\u003eQuinolone antibiotics: Animal data indicate that NSAIDs may increase the risk of seizures associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may be at increased risk of developing seizures.\u003c\/p\u003e\n\u003cp\u003eSelective serotonin reuptake inhibitors (SSRIs): There is an increased risk of gastrointestinal ulceration or bleeding (see section 4.4).\u003c\/p\u003e\n\u003cp\u003eTacrolimus: An increased risk of nephrotoxicity is possible when NSAIDs are administered concomitantly with tacrolimus.\u003c\/p\u003e\n\u003cp\u003eZidovudine: There is an increased risk of haematological toxicity when NSAIDs are administered concomitantly with zidovudine.\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePediatric population\u003c\/u\u003e: No additional information available.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSIDE EFFECTS\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHypersensitivity reactions to NSAIDs have been reported and these may consist of: (a) non-specific allergic reactions and anaphylaxis; (b) respiratory tract reactivity, e.g. asthma, aggravated asthma, bronchospasm, dyspnoea; (c) various skin reactions, e.g. pruritus, urticaria, angioedema and, more rarely, exfoliative and bullous dermatosis (including epidermal necrolysis and erythema multiforme). Edema, hypertension and heart failure have been reported in association with treatment with NSAIDs. Data are insufficient to exclude this risk with the use of flurbiprofen oral mucosal spray, solution. \u003cb\u003eThe list of adverse effects reported below refers to those recorded with flurbiprofen, used at doses compatible with the OTC classification and for a short period\u003c\/b\u003e. (Very common (≥1\/10), Common (≥1\/100 to \u003c1\/10), Uncommon (≥1\/1,000 to \u003c1\/100), Rare (≥1\/10,000 to \u003c1\/1,000), Very rare (\u003c1\/10,000), Not known (cannot be estimated from the available data)). \u003ci\u003ePathologies of the blood and lymphatic system\u003c\/i\u003e. Not known: anemia, thrombocytopenia. \u003ci\u003eCardiovascular and cerebrovascular diseases\u003c\/i\u003e. Not known: edema, hypertension, heart failure. \u003ci\u003eNervous system disorders\u003c\/i\u003e. Common: dizziness, headache, paraesthesia; Uncommon: drowsiness. \u003ci\u003eRespiratory, thoracic and mediastinal disorders\u003c\/i\u003e. Common: throat irritation; Uncommon: exacerbation of asthma and bronchospasm, dyspnoea, wheezing, oropharyngeal vesicular rash, hypoesthesia of the pharynx. \u003ci\u003eGastrointestinal disorders\u003c\/i\u003e. Common: diarrhoea, mouth ulceration, nausea, oral pain, oral paraesthesia, oropharyngeal pain, oral discomfort (warm or burning sensation, tingling in the mouth); Uncommon: abdominal distension, abdominal pain, constipation, dry mouth, dyspepsia, flatulence, glossodynia, dysgeusia, oral dysesthesia, vomiting. \u003ci\u003ePathologies of the skin and subcutaneous tissue\u003c\/i\u003e. Uncommon: various types of skin rashes, itching; Not known: severe forms of skin reactions such as bullous reactions, including Stevens-Johnson syndrome and toxic epidermal necrosis. \u003ci\u003eGeneral pathologies and conditions relating to the administration site\u003c\/i\u003e. Uncommon: pyrexia, pain. \u003ci\u003eImmune system disorders\u003c\/i\u003e. Rare: anaphylactic reaction. \u003ci\u003ePsychiatric disorders\u003c\/i\u003e. Uncommon: insomnia. \u003ci\u003eHepatobiliary disorders\u003c\/i\u003e. Not known: hepatitis. \u003cu\u003eReporting of suspected adverse reactions\u003c\/u\u003e. Reporting suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit\/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOVERDOSE\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eSymptoms\u003c\/b\u003e The majority of patients who have ingested clinically significant quantities of NSAIDs will no longer develop nausea, vomiting, epigastric pain, or more rarely diarrhea. Tinnitus, headache, and gastrointestinal bleeding are also possible. In cases of more severe NSAID intoxication, central nervous system toxicity is observed, manifested by drowsiness, occasionally excitation, blurred vision and disorientation or coma. Occasionally patients develop seizures. In severe NSAID intoxication, metabolic acidosis may occur and the prothrombin time\/INR may be prolonged, probably due to interference with the action of circulating coagulation factors. Acute renal failure and liver damage may occur. An exacerbation of asthma is possible in asthmatic subjects. \u003cb\u003eTreatment\u003c\/b\u003e Treatment should be symptomatic and supportive and should include maintaining a patent airway and monitoring cardiac function and vital signs until stabilization. Oral administration of activated charcoal or gastric lavage and, if necessary, correction of serum electrolytes should be considered if the patient presents within one hour of ingesting a potentially toxic amount. Seizures, if they are frequent or prolonged, should be treated with intravenous diazepam or lorazepam. Administer bronchodilators for asthma. There is no specific antidote for flurbiprofen.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePREGNANCY AND BREASTFEEDING\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cu\u003ePregnancy\u003c\/u\u003e: Inhibition of prostaglandin synthesis may negatively influence pregnancy and\/or embryonic\/fetal development. Data obtained from epidemiological studies suggest an increased risk of miscarriage, cardiac malformation and gastroschisis following the use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiovascular malformation was increased from less than 1% to approximately 1.5%. The risk is thought to increase with the dose and duration of therapy. In animals, it has been shown that the administration of a prostaglandin synthesis inhibitor causes an increase in pre- and post-implantation losses and embryo-foetal lethality. In addition, an increased incidence of several malformations, including cardiovascular ones, has been reported in animals administered a prostaglandin synthesis inhibitor during the organogenetic period. Flurbiprofen should not be administered during the first and second trimester of pregnancy. During the third trimester of pregnancy, all inhibitors of prostaglandin synthesis can expose • the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction which may progress to renal failure with oligo-hydramnios; • the mother and newborn, at the end of pregnancy, to: - possible prolongation of bleeding time, an anti-aggregating effect which can occur even at very low doses. - inhibition of uterine contractions resulting in a delay or prolongation of labor. Consequently, flurbiprofen is contraindicated during the third trimester of pregnancy (see section 4.3). \u003cu\u003eBreastfeeding\u003c\/u\u003e: In a limited number of studies, flurbiprofen appears in breast milk at very low concentrations and is unlikely to have adverse effects on the breastfed infant. However, due to the possible adverse effects of NSAIDs on breast-fed infants, the use of flurbiprofen spray by breastfeeding mothers is not recommended. \u003cu\u003eFertility\u003c\/u\u003e: There is some evidence to suggest that cyclooxygenase\/prostaglandin synthesis inhibitors may cause impairment of female fertility through an effect on ovulation. This is reversible upon discontinuation of treatment.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eEFFECTS ON DRIVING ABILITY\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNo studies on the effects on the ability to drive and use machines have been performed. Dizziness, drowsiness and visual disturbances are possible side effects following the intake of NSAIDs. If these occur, the patient should not drive or use machinery.\u003c\/p\u003e","brand":"Reckitt Benckiser","offers":[{"title":"Default Title","offer_id":51730210324807,"sku":"048231017","price":12.93,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/reckitt-benckiser-h-it-spa-benactivdolmed-8-75-mg-dose-15-ml-spray-orale-limone-e-miele-farmacia-dottor-tili-1213791050.jpg?v=1767154809"}],"url":"https:\/\/www.dottortili.com\/en-eu\/collections\/benactiv.oembed","provider":"Farmacia Dottor Tili","version":"1.0","type":"link"}